Parker Waichman LLP Files One of the First NAION Eye Injury Cases against Novo Nordisk in the Superior Court of New Jersey, Middlesex County

PORT WASHINGTON, N.Y., April 15, 2025 /PRNewswire/ -- ParkerWaichman LLP, a nationally recognized law firm dedicated to representing victims of defective drugs and devices, recently filed a lawsuit against Novo Nordisk on behalf of a New Jersey based Plaintiff diagnosed with non-arteritic anterior ischemic optic neuropathy (NAION). NAION, a debilitating eye condition, islinked tothe active ingredient, semaglutide, in Ozempic and Wegovy. The case is now pending in the Superior Court of New Jersey, Middlesex County.

Parker Waichman LLP is urging individuals who have sufferedserious eye injuriesafter taking these widely prescribed GLP-1 receptor agonist medications to contact the firm for afree case review. These medications, originally developed to treat Type 2 diabetes, have surged in popularity for weight loss. However, recent studies have uncovered a disturbing link between semaglutide (Ozempic/Wegovy) and NAION, a condition that causes permanent vision loss by cutting off blood flow to the optic nerve. Patients who took these drugs have reportedsudden blindness, optic nerve damage, and other irreversible complications, raising concerns about thefailure of drug manufacturers to warn consumers and medical professionalsabout these risks.

A2025 study published in JAMA Ophthalmologyexaminednine patientswho developedoptic nerve disordersafter using GLP-1 medications, with the majority suffering from NAION-like symptoms. Additional research fromHarvard's Mass Eye and Ear Institutefound thatdiabetic users of semaglutide were four times more likely to develop NAION, while non-diabetic users taking the drug for weight loss faced asevenfold increased risk.

Despite growing scientific evidence,Novo Nordisk continues to downplay the dangersassociated with these medications, failing to includeadequate warningsabout the risk of permanent blindness.

Parker Waichman LLP Fighting for Victims Nationwide

"NAION is a devastating, permanent eye injury. Studies from multiple, reputable institutions, have shown a statistically significant relationship between semaglutide (the active ingredient in Ozempic) and NAION. Despite this evidence, Novo Nordisk continues to deny reality by failing to warn consumers and medical professionals about this horrific injury and must be held accountable,"saidJason S. Goldstein, Senior Litigation Counsel at Parker Waichman LLP.

Parker Waichman LLP iscurrently accepting cases nationwidefor individuals who have suffered vision loss, blindness, or serious optic nerve damage after takingOzempic or Wegovy. Victims may be entitled tocompensation for medical expenses, lost wages, pain and suffering, and other damages.

Free Case Review for Affected Individuals

If you or a loved oneexperienced sudden vision loss, blindness, or optic nerve damageafter usingOzempic or Wegovy, you may have alegal claim against the drug manufacturers. Parker Waichman LLP is offeringfree, no-obligation case evaluationsto help victims understand their rights and pursue justice.

Contact Parker Waichman LLP Today

For a free consultation, call 1-800-YOUR-LAWYER (1-800-968-7529) or visit YourLawyer.com to learn more about your legal options and how to protect your rights.

About Parker Waichman LLP

Parker Waichman LLP is a nationally recognized law firm dedicated to fighting for victims ofdefective drugs, dangerous products, accidents, and corporate negligence. With a proven track record ofholding pharmaceutical companies accountable, the firm has securedbillions in settlements and verdictsfor injured clients.

Media Contact:

Parker Waichman LLP
Phone:1-800-YOUR-LAWYER (1-800-968-7529)
Website:www.yourlawyer.com

SOURCE Parker Waichman LLP